Never too old to benefit from lipid-lowering treatment
- 21 November 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 396 (10263), 1608-1609
- https://doi.org/10.1016/S0140-6736(20)32333-3
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohortThe Lancet, 2020
- Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsThe Lancet, 2020
- The therapeutic age paradox coming to an endEuropean Heart Journal, 2019
- 20-Year Follow-up of Statins in Children with Familial HypercholesterolemiaThe New England Journal of Medicine, 2019
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal, 2019
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsThe Lancet, 2019
- Statin Prescribing in the Elderly: Special ConsiderationsCurrent Atherosclerosis Reports, 2017
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 2017
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization AnalysisJournal of the American College of Cardiology, 2012
- Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth?European Heart Journal, 2012